- Service Name
AseptSoft
- Industry
Pharmaceutical, Biopharmaceutical, Process Technology, Liquid Sterile Technology
- Main Value Proposition
AseptSoft significantly increases efficiency in pharmaceutical process design, saving time and costs.
- Description
AseptSoft is a software add-on developed by Aseptconn to enhance efficiency in pharmaceutical process design. It offers a free 30-day trial for users to test its capabilities.
- Key Features
Free 30-day trial; Comprehensive digitalization of pharmaceutical process design; Technical consulting and calculations by process experts; CFD simulations for various processes
- Use Cases
Pharmaceutical process design optimization; CFD simulations for flow and mixing processes; Technical consulting for process industries
- Competitive advantages
Extensive portfolio of proprietary products and services; Expert technical consulting tailored to client needs; Strong reputation as a preferred supplier for major international pharmaceutical companies
- Strengths
Aseptconn's strengths lie in its innovative products, expert consulting, and comprehensive service offerings that improve client processes sustainably.
- Positioning
Aseptconn positions itself as a leading provider of components, systems, software, and services for liquid sterile technology.
- Audience
The primary target users are professionals in the pharmaceutical and biopharmaceutical industries, including process engineers and technical managers.
- CTA
Test for free now.
- Tags
Pharmaceutical Process Design
CFD Simulations
Technical Consulting
Liquid Sterile Technology
- Tagline
The revolution in pharmaceutical process design.
- Tone of Voice
Professional, informative, supportive
- Differentiation
Aseptconn combines a wide range of technical components and expert consulting services, making it a one-stop shop for the pharmaceutical and biopharmaceutical industries.
- Brand Positioning
Aseptconn is recognized as a trusted partner in the pharmaceutical industry, known for its quality products and expert services.
- Founded
2016-01-01